Table 6 Completed and ongoing clinical trial of NK cell-based therapy for solid tumors
From: NK cell-based cancer immunotherapy: from basic biology to clinical development
Cancer type | Therapy | Phase | NCT | Status |
|---|---|---|---|---|
Gastric cancer | Allogeneic UCB-NK cells | N/A | NCT04385641 | Ongoing |
Autologous NK cells combined with Trastuzumab | I/II | NCT02030561 | Unknown No outcome reported | |
Pancreatic cancer | ROBO1 CAR-NK cells | I/II | NCT03941457 | Ongoing |
ROBO1 specific BiCAR-NK/T cells | I/II | NCT03931720 | Ongoing | |
Tongue cancer | Cryosurgery combined with NK cells | I/II | NCT02849379 | Completed No outcome reported |
Esophageal cancer | Cryosurgery combined with NK cells | I/II | NCT02843581 | Completed No outcome reported |
Laryngeal cancer | Cryosurgery combined with NK cells | I/II | NCT02849314 | Completed No outcome reported |
Pharyngeal cancer | Cryosurgery combined with NK cells | I/II | NCT02849327 | Completed No outcome reported |
Cancer lack of MHC-I expression | Autologous-induced T cell like NK cells | I/II | NCT03882840 | Ongoing |
Small cell lung cancer | Autologous NK cells | II | NCT03410368 | Unknown No outcome reported |
Non-small cell lung cancer | CCCR-modified NK92 cell | I | NCT03656705 | Enrolling |
Hsp70-peptide TKD/IL-2 activated, autologous NK cells | II | NCT02118415 | Suspended | |
Autologous NK cells | I | NCT03662477 | Ongoing | |
Cryosurgery combined with allogeneic NK cells | I/II | NCT02843815 | PMID: 28508945 Showed preliminary efficacy | |
Cetuximab combined with NK | I/II | NCT02845856 | Completed No outcome reported | |
Renal cancer | Cryosurgery combined with NK | I/II | NCT02843607 | Completed No outcome reported |
Breast cancer | Cryosurgery combined with NK | I/II | NCT02844335 | Completed No outcome reported |
Trastuzumab combined with NK | I/II | NCT02843126 | Completed No outcome reported | |
Ovarian cancer | Cryosurgery combined with NK | I/II | NCT02849353 | Completed No outcome reported |
Cervical cancer | Cryosurgery combined with NK | I/II | NCT02849340 | Completed No outcome reported |
Neuroblastoma | Autologous NK combined with antibody ch14.18 and lenalidomide | I | NCT02573896 | Ongoing |
Allogeneic NK combined with the anti-GD2 antibody | I/II | NCT03242603 | Unknown No outcome reported | |
Liver cancer | Cryosurgery combined with NK | I/II | NCT02843802 | Completed No outcome reported |
Allogeneic NK | I | NCT01147380 | Completed No outcome reported | |
Irreversible electroporation and autologous NK | I/II | NCT03008343 | Completed No outcome reported | |
Cryosurgery combined with NK | I/II | NCT02849015 | Completed No outcome reported | |
High-risk solid tumor | Allogeneic NK cells with human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) | II | NCT02100891 | Ongoing |
Metastatic HER2-expressing solid tumor | Allogeneic ACE1702 (anti-HER2 oNK cells) | I | NCT04319757 | Ongoing |
Solid tumor expressing ROBO1 | ROBO1 CAR-NK cells | I/II | NCT03940820 | Ongoing |
MUC1-positive solid tumor | Allogeneic anti-MUC1 CAR-pNK cells | I/II | NCT02839954 | PMID: 28054442 Show preliminary efficacy |
Late-stage malignancies | Autologous NK cell combined with nimotuzumab | I | NCT03554889 | Unknown No outcome reported |
Recurrent malignant solid tumor | NK cell combined with Bevacizumab | I/II | NCT02857920 | Completed No outcome reported |
NK cells | I | NCT03619954 | Unknown No outcome reported | |
Pediatric solid tumor | Autologous NK cell | I | NCT01875601 | Completed No outcome reported |